Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Danish Headache Center
Modality
protein_peptide
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03881644CT.gov PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine | — | Completed | — | — | — |
NCT02364453CT.gov The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients | — | Completed | — | — | — |
NCT01471990CT.gov Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance | — | Completed | — | — | — |
NCT00380263CT.gov PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Without Aura
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pacap-38 (this asset) | Danish Headache Center | N/A | D · 30 |
| Topiramate | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | P4 | BBB |
| DHE | Satsuma Pharmaceuticals, Inc. | P3 | BBB |
| Apsolol | Norwegian University of Science and Technology | P3 | BB |
| Metoclopramide | Assistance Publique - Hôpitaux de Paris | P4 | BB |
| Rimegepant | University of South Florida | P4 | BB |
| Dexketoprofen | Kecioren Education and Training Hospital | P4 | BB |
| Almotriptan | Messoud Ashina, MD | P4 | BB |
| Ibuprofen | Kecioren Education and Training Hospital | P4 | BB |
+42 more in the Migraine Without Aura cohort
Other indications for Pacap-38
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P1 | CC · 42 |
| Headache Disorder | — | N/A | D · 30 |
| Migraine With Aura | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pacap-38 in Migraine Without Aura. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pacap-38-migraine-without-aura
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →